Sunday, June 14, 2026

Patent directory · USPTO A61K / A61P

Browse patents

Browse 30,257 pharma-relevant patents (US A61K/A61P) linked to tracked companies, drugs, and pipeline programs.

Patents indexed 30,257
Companies 1,769
Drugs linked 4,797

Quick answer

NovaPharmaNews indexes 30,257 US pharmaceutical patents from USPTO PatentsView (CPC A61K/A61P), cross-linked to company assignees, drug INN profiles, and pipeline programs. Search by patent number, applicant, title, or CPC code — or use facet hubs for expiring patents, assignees, and therapeutic areas.

Patent results

Page 283 of 1,261
  1. WO 2022029639

    FORMULATIONS PHARMACEUTIQUES AMÉLIORÉES COMPRENANT DES INHIBITEURS DE PI3K

    BERLIN CHEMIE AG [DE] · Granted Feb 10, 2022 · Expires Feb 5, 2042

    granted
  2. US 11241436

    Autophagy inducers for treatment of CNS conditions

    THE UNITED STATES OF AMERICA, represented by the Secretary, Department of Health and Human Services · Granted Feb 8, 2022 · Expires Feb 3, 2042

    granted
  3. US 11241456

    Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy

    Iovance Biotherapeutics, Inc. · Granted Feb 8, 2022 · Expires Feb 3, 2042

    granted
  4. US 11242543

    Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription

    The Regents of the University of California · Granted Feb 8, 2022 · Expires Feb 3, 2042

    granted
  5. US 11243213

    Kits and methods for prediction and treatment of preeclampsia

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Feb 8, 2022 · Expires Feb 3, 2042

    granted
  6. US 11242339

    Chemical inhibition of the E3 ligase subunit FBXO7 confers neuroprotection and anti-inflammatory activity by stabilizing mitochondria

    United States Government as represented by the Department of Veterans Affairs · Granted Feb 8, 2022 · Expires Feb 3, 2042

    granted
  7. US 11241499

    Human serum albumin in formulations

    REGENERON PHARMACEUTICALS, INC. · Granted Feb 8, 2022 · Expires Feb 3, 2042

    granted
  8. US 11241458

    Cell preparations for extemporaneous use, useful for healing and rejuvenation in vivo

    RegenLab USA LLC · Granted Feb 8, 2022 · Expires Feb 3, 2042

    granted
  9. US 11241394

    Treating vasculature related diseases or disorders using nanoparticles

    The Regents of the University of California · Granted Feb 8, 2022 · Expires Feb 3, 2042

    granted
  10. US 11242510

    Mammalian cells devoid of lactate dehydrogenase activity

    The Regents of the University of California · Granted Feb 8, 2022 · Expires Feb 3, 2042

    granted
  11. US 11242400

    CD123 binding proteins and related compositions and methods

    Aptevo Research and Development LLC · Granted Feb 8, 2022 · Expires Feb 3, 2042

    granted
  12. US 11242377

    Chimeric receptor with ligand binding exodomain and cytokine and T cell signalling endodomains

    AUTOLUS LIMITED · Granted Feb 8, 2022 · Expires Feb 3, 2042

    granted
  13. US 11242335

    Fluorine-substituted indazole compounds and uses thereof

    SUNSHINE LAKE PHARMA CO., LTD. · Granted Feb 8, 2022 · Expires Feb 3, 2042

    granted
  14. US 11241512

    Stabilized radio-labeled anti-CD45 immunoglobulin compositions

    Actinium Phamaceuticals, Inc. · Granted Feb 8, 2022 · Expires Feb 3, 2042

    granted
  15. US 11242333

    Inhibitors of plasma kallikrein

    KalVista Pharmaceuticals Limited · Granted Feb 8, 2022 · Expires Feb 3, 2042

    granted
  16. US 11241498

    Room temperature stable lyophilized protein

    REGENERON PHARMACEUTICALS, INC. · Granted Feb 8, 2022 · Expires Feb 3, 2042

    granted
  17. US 11241483

    Methods of treating mild brain injury

    The Regents of the University of California · Granted Feb 8, 2022 · Expires Feb 3, 2042

    granted
  18. US 11241473

    Bicyclic peptide ligands and uses thereof

    BicycleTx Limited · Granted Feb 8, 2022 · Expires Feb 3, 2042

    granted
  19. US 11241460

    Photoreceptors and photoreceptor progenitors produced from pluripotent stem cells

    Astellas Institute for Regenerative Medicine · Granted Feb 8, 2022 · Expires Feb 3, 2042

    granted
  20. US 11241451

    Modulators of IRF4 expression

    Ionis Pharmaceuticals, Inc. · Granted Feb 8, 2022 · Expires Feb 3, 2042

    granted
  21. US 11241478

    Adenovirus-associated viral vectors for expressing variants of tetratricopeptide repeat (TPR)-containing Rab8b interacting (TRIP8b) protein in neurons and uses thereof for treating major depressive disorder (MDD)

    Northwestern University · Granted Feb 8, 2022 · Expires Feb 3, 2042

    granted
  22. US 11241445

    Vaginal inserted estradiol pharmaceutical compositions and methods

    Compass Therapeutics LLC · Granted Feb 8, 2022 · Expires Feb 3, 2042

    granted
  23. US 11241380

    Porous photonic crystals for drug delivery to the eye

    The Regents of the University of California · Granted Feb 8, 2022 · Expires Feb 3, 2042

    granted
  24. US 11241415

    N-methyl-N-(1-phenyl-2-(1-pyrrolidinyl)ethyl)-2-aminophenylacetamide derivatives agonists for the κ opioid receptor

    Nektar Therapeutics · Granted Feb 8, 2022 · Expires Feb 3, 2042

    granted

Frequently asked questions

What patents are included in this directory?

We index 30,257 published US pharma-relevant patents filtered to CPC classes A61K and A61P, with assignee links to our company directory where a match exists.

How do I search for a patent?

Use the search box to match patent number, title, applicant name, or CPC classification (e.g. A61K). For cross-entity queries spanning news and drugs, use the global search.

How is this different from the patent intelligence dashboard?

The dashboard at /patents highlights expirations, recent grants, and assignee rankings. Browse is the full paginated directory with search — best for looking up a specific filing or applicant portfolio slice.